Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study

1999 • 1,549 citations

Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

1992 • 784 citations

Cardiovascular and Cerebrovascular Events in Patients Treated for Human Immunodeficiency Virus Infection

2003 • 638 citations

Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors

1999 • 615 citations

A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease

1995 • 569 citations

Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV Infection

2000 • 499 citations

Effects of Protease Inhibitors on Hyperglycemia, Hyperlipidemia, and Lipodystrophy

2000 • 465 citations

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects

2000 • 398 citations

Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study

2002 • 274 citations

Factors Related to Lipodystrophy and Metabolic Alterations in Patients with Human Immunodeficiency Virus Infection Receiving Highly Active Antiretroviral Therapy

2002 • 260 citations

Preliminary Guidelines for the Evaluation and Management of Dyslipidemia in Adults Infected with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group

2000 • 201 citations

Virological, Immunological, and Clinical Impact of Switching from Protease Inhibitors to Nevirapine or to Efavirenz in Patients with Human Immunodeficiency Virus Infection and Long-Lasting Viral Suppression

2002 • 176 citations

Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse‐Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1–Infected Protease Inhibitor–Experienced Patients

2002 • 153 citations

Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study.

2000 • 153 citations

Coronary Artery Disease and Human Immunodeficiency Virus Infection

2000 • 135 citations

Effects of HIV protease inhibitor therapy on lipid metabolism

2003 • 130 citations

An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients

2001 • 128 citations

Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART

2003 • 126 citations

Hyperlipidemia Associated with HIV Protease Inhibitor Use: Pathophysiology, Prevalence, Risk Factors and Treatment

2000 • 124 citations

Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era

2003 • 85 citations

Lopinavir Plasma Concentrations and Changes in Lipid Levels During Salvage Therapy with Lopinavir/Ritonavir-Containing Regimens

2003 • 85 citations

Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors

2002 • 83 citations

Use of Fibrates in the Management of Hyperlipidemia in HIV-Infected Patients Receiving HAART

2002 • 74 citations

Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy

2003 • 68 citations

Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors

2002 • 65 citations

Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: ‘a call for cardiovascular prevention’

2002 • 54 citations

Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy

2000 • 52 citations

Long‐Term Metabolic Consequences of Switching from Protease Inhibitors to Efavirenz in Therapy for Human Immunodeficiency Virus–Infected Patients with Lipoatrophy

2002 • 49 citations

Amprenavir: A new human immunodeficiency virus type 1 protease inhibitor

2000 • 48 citations

Differentiating hyperlipidaemia associated with antiretroviral therapy

2003 • 33 citations

What are the perceived advantages and disadvantages of non‐nucleoside reverse transcriptase inhibitors as first‐line therapy?

2000 • 8 citations